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Abstract 30 
Both normal tissue development and cancer growth are driven by a branching 31 
process of cell division and mutation accumulation that leads to intra-tissue 32 
genetic heterogeneity. However, quantifying somatic evolution in humans 33 
remains challenging. Here, we show that multi-sample genomic data from a 34 
single time point of normal and cancer tissues contains information on single-cell 35 
divisions. We present a new theoretical framework that, applied to whole-36 
genome sequencing data of healthy tissue and cancer, allows inferring the 37 
mutation rate and the cell survival/death rate per division. On average, we found 38 
that cells accumulate 1.14 mutations per cell division in healthy haematopoiesis 39 
and 1.37 mutations per division in brain development. In both tissues, cell 40 
survival was maximal during early development. Analysis of 131 biopsies from 41 
16 tumours showed 4 to 100 times increased mutation rates compared to 42 
healthy development and substantial inter-patient variation of cell 43 
survival/death rates.  44 
 45 
Introduction 46 
Most cells in human tissues have a limited life span and need to be replenished 47 
for tissues to remain functional1-3. This cell turnover leads to somatic evolution, 48 
with cells accumulating mutations upon which selection may act4,5. Inter- and 49 
intra-tumour genetic heterogeneity6,7 as well as treatment resistance8,9 are now 50 
understood to be consequences of somatic evolutionary processes. Recent 51 
studies demonstrate somatic evolution in healthy non-cancerous tissues 52 
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throughout live10-14. Normal brain cells carry hundreds of mutations weeks after 53 
conception12 and normal skin or esophagus cells accumulate hundreds of cancer 54 
driver mutations during adulthood10,11.  55 
These observations call for a better quantitative understanding of the somatic 56 
evolutionary forces in both cancerous and healthy tissues15. However, unlike 57 
species evolution for which a timed fossil record exists16,17, the lack of sequential 58 
human data over time due to ethical and technical limitations is a major obstacle. 59 
Furthermore, some evolutionary forces are difficult to measure even having the 60 
data. For example, the mutational burden in a tissue is the combined effect of 61 
per-cell mutation and per-cell survival rates, which remain hidden in sequencing 62 
data18,19 (Figure 1). Currently, we cannot independently infer these two for 63 
somatic evolution fundamental quantities from single time point sequencing 64 
data.  65 
Here, we show that multiple bulk or single cell sequencing from the same patient 66 
contain recoverable information on these important quantities that can be 67 
recovered with evolutionary theory. This allows inferring in vivo cell mutation 68 
and cell survival rates in tissues of individual humans from single time point 69 
sequencing data.  70 
 71 
We draw our inferences by defining and quantifying the distribution of 72 
mutational distances amongst multiple samples. We first discuss the required 73 
theoretical considerations and derive an analytical expression for the expected 74 
distribution of mutational distances from multi-sample sequencing data. We 75 
introduce a Bayesian sampling framework based on the mutational distance 76 
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distribution, allowing us to disentangle mutation rates per cell division and cell 77 
survival/death rates. We apply this framework to whole genome single cell 78 
sequencing data of haematopoiesis and brain tissue and measure both 79 
evolutionary parameters during early development. Finally, we utilize multi-80 
sample sequencing data on 16 tumours to infer patient specific evolutionary 81 
parameters in human cancers.  82 
Results 83 
The distribution of mutational distances 84 
All cells in a human tissue must have descended from a most recent common 85 
ancestor cell (MRCA) that existed briefly during early development. Similarly, all 86 
cells in a sample of a tissue must have descended from a (different) MRCA that 87 
was present in that tissue at an earlier time (Figure 1a). Mutations found in all 88 
cells of the sample (clonal mutations) were present in this MRCA. If we take 89 
multiple samples of the same tissue, we can reconstruct the mutational profile 90 
(all mutations carried by a single cell) of multiple ancestral cells (Figure 1a). 91 
Typically, these ancestral cells differ in their exact mutational profile between 92 
one another, because mutations inevitably accumulate differently in distinct 93 
lineages (Figure 1b). We use the differences of the mutational profiles between 94 
ancestral cells to construct the distribution of mutational distances. We define a 95 
mutational distance as the number of mutations different between any two 96 
ancestral cells (Figure 1c). In the language of set theory, if ancestral cell 1 carries 97 
a set of mutations ܣ and ancestral cell 2 carries a set of mutations ܤ, then by 98 
definition, both cells must have coalesced from an earlier ancestral cell (Figure 99 
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1a). The mutational profile of this cell is given by the intersection ܣ ∩ ܤ. This 100 
allows us to construct two mutational distances given by  101 
 102 
                         ݕଵ = |ܣ ∖ (ܣ⋂ܤ)|              and             ݕଶ = |ܤ ∖ (ܣ⋂ܤ)|.                      (1) 103 
 104 
This process can be iterated for increasing combinations of samples per tumour.  105 
We now turn to quantitative expressions for the expected distribution of 106 
mutational distances ܲ(ݕ). In a single division, the probability of a cell to acquire 107 
ܺ novel mutations follows a Poisson distribution 108 
 109 
                                                     ܲ(ܺ) = (ఓ௅)೉௑! ݁ିఓ௅.                                                        (2) 110 
 111 
Here, ߤ is the mutation rate (in units of base pairs per cell division) and ܮ the size 112 
of the sequenced genome. Throughout the manuscript, we assume a constant 113 
mutation rate and do not consider more punctuated catastrophic events or 114 
mutational bursts. Distances between cells of a lineage may arise from more than 115 
a single cell division. Instead, double, triple and higher modes of cell division 116 
contribute to the distribution of mutational distances of multi-sample samples. 117 
In general, a cell accumulates ଵܺ + ܺଶ + ⋯ + ܺ௡ number of novel mutations after 118 
݊ divisions, which is again Poisson distributed. 119 
 120 
In addition, we must account for cell death or differentiation, leading to lineage 121 
loss. We therefore introduce a probability ߚ of having two surviving lineages 122 
after a cell division and a probability 1 − ߚ of a single surviving lineage (cell 123 
death). We can split the total of ݊ cell divisions into ݎ divisions that result in two 124 
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surviving lineages (branching divisions) and ݉ divisions with only a single 125 
surviving lineage (non-branching divisions). The number of non-branching 126 
events ݉ is again a random variable, which follows a Negative Binomial 127 
distribution  128 
 129 
                                  ܲ(݉|ݎ) = ቀݎ + ݉ − 1ݎ − 1 ቁ ߚ
௥(1 − ߚ)௠.                                         (3) 130 
 131 
The number of mutations acquired between two branching divisions depends 132 
jointly on the Poisson distributed number of mutations and the Negative binomial 133 
distributed number of non-branching divisions ݉. Formally, we can write for the 134 
total number of mutations between two branching divisions 135 
 136 
                                                                ܻ = ∑ ௜ܺ௠௜ୀଵ .                                                               (4) 137 
 138 
Equation (4) is a random sum of random variables and different combinations of 139 
ܺ and ݉ imply the same mutational burden ܻ within a single cell lineage. 140 
Intuitively, a measured mutational burden in a single lineage can result from 141 
either many non-branching divisions with a low mutation rate or, alternatively a 142 
few non-branching divisions with high mutation rate. The mutational burden of a 143 
single sample is insufficient to disentangle per-cell mutation and per-cell 144 
survival/death rates.  145 
 146 
We therefore turn to the number of mutations different between ancestral cells. 147 
Suppose two ancestral cells are separated by ݎ branching divisions. Following 148 
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from equation (4), we can calculate the probability distribution of the number of 149 
acquired mutations ܲ(ݕ|ݎ) after ݎ branching divisions 150 
 151 
                        ܲ(ݕ|ݎ) = ∑ ቀ݅ − 1ݎ − 1ቁ ߚ
௥(1 − ߚ)௜ି௥݁ି௜ఓ௅ (௜ఓ௅)೤௬!ஶ௜ୀ௥ .                        (5) 152 
 153 
Here the sum starts at ݎ, as we need to have at least ݎ branching divisions and 154 
runs to infinity as in principal infinitely many non-branching divisions can occur 155 
(with vanishingly low probability). Finally, we need the expected distribution of 156 
branching divisions ܲ(ݎ) in a growing population of cells, which follow from 157 
coalescence theory20-22. For a growing population, e.g. human tissues during 158 
early development or cancer growth, we find   159 
 160 
                                         ܲ(ݎ) =
ୣ୶୮ቆି೐షഁ(ೝశభ)ഁ ቇିୣ୶୮ቆି
೐షഁೝ
ഁ ቇ
ଵିୣ୶୮൬ି೐షഁഁ ൰
.                                                (6) 161 
 162 
We provide a more detailed derivation in the Methods. Combining equations (5) 163 
and (6) we arrive at the final expression for the expected distribution of 164 
mutational distances in an exponentially growing population  165 
 166 
                 ܲ(ݕ) = ∑ ∑ ܲ(ݎ) ቀ݅ − 1ݎ − 1ቁ ߚ
௥(1 − ߚ)௜ି௥݁ି௜ఓ௅ (௜ఓ௅)೤௬!ஶ௜ୀ௥ஶ௥ୀଵ .                 (7) 167 
 168 
The two evolutionary parameters of interest here, the mutation rate per cell 169 
division ߤ and the cell survival rate ߚ, disentangle in equation (7). There are 170 
approximately four possible regimes for the distribution of mutational distances, 171 
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discriminated by uni- or multimodality determined by combinations of small or 172 
large ߤ and ߚ. In Figure 2a we show four representative realisations of equation 173 
(7). The distribution of mutational distance is unimodal for sufficiently small 174 
mutation rate ߤ (bottom panels in Figure 2a) with a single peak at the mean 175 
mutational distance ߤܮ. The per-cell survival probability ߚ  determines the 176 
weight of the distribution towards larger distances. For ߚ = 1 the distribution is 177 
sharply located around the mean mutation rate. However, for smaller ߚ more 178 
weight is given to larger distances and the distribution gets a fat tail. The same is 179 
true for the case of high mutation rate ߤ, except the distribution is multi-modal 180 
with peaks separated by multiples of the mean mutational distance ߤܮ (Figure 181 
2a). Again, ߚ determines the weight to higher mutational distances with lower ߚ 182 
causing a distribution with a long oscillating tail (top right panel in Figure 2a). 183 
Note, the ݕ-axes in Figure 2a correspond to the probabilities of observing certain 184 
mutational distances. Lower probabilities require a higher resolution and 185 
therefore more sampling to resolve the exact shape of the distribution. In 186 
practice, the distribution of mutational distances is easiest to recover from data 187 
with low ߤ and high ߚ (fewest number of tissue samples required), whereas most 188 
samples are required for high ߤ and low ߚ (top right panel in Figure 2a).   189 
 190 
Computational validation and MCMC inference framework 191 
We implemented stochastic spatial simulations of mutation accumulation in 192 
growing tissues using previously published code23. Briefly, cell birth and death 193 
on a 2- or 3-dimensional grid was simulated using a Gillespie algorithm24. During 194 
division, cells accumulate a number of new mutations drawn from a Poisson 195 
distribution. Simulations were stopped when the tissue reached ~1 million cells. 196 
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This allowed us to take samples (either single cells or bulks) and construct all 197 
pairwise mutational distances of all ancestral cell lineages detectable in the 198 
samples. In Figure 2b we show an example of the mutational distance 199 
distribution derived from 200 samples of a stochastic simulation (dots) 200 
compared to the theoretical prediction (dashed line).  201 
We want to infer the microscopic evolutionary parameters ߤ and ߚ given a 202 
measured distribution of mutational distances. This can be done by Markov 203 
chain Monte Carlo methods (MCMC). We implemented a standard Metropolis-204 
Hastings algorithm. In brief, a random pair of parameters ߤ and ߚ is drawn from 205 
uninformed uniform distributions and the likelihood of the model parameters 206 
given the data is calculated. The new set of parameters is accepted with a 207 
probability proportional to the likelihood ratio of the new and old parameter set 208 
(see Methods for more details). This framework recovers the true underlying 209 
parameters from stochastic simulations (Figure 2c & Supplementary Figures 17 210 
to 21 ).  211 
 212 
In vivo mutation and cell survival rate inference in healthy 213 
haematopoiesis during early development 214 
We discuss the in vivo mutation accumulation in healthy haematopoiesis during 215 
early development as a first application. The cell population is growing and we 216 
expect a low mutation rate and a high per-cell survival rate during the 217 
development of early haematopoiesis13,25. In a recent study, Lee-Six and 218 
colleagues13 sequenced the genome of 89 healthy haematopoietic stem cells of a 219 
single 59-year-old male and subsequently constructed the phylogeny of healthy 220 
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haematopoiesis. They estimated the per-cell mutation rate to be 1.2 mutations 221 
per genome per division during early development assuming perfect cell 222 
doublings. Using the same data we construct the pairwise mutational distances 223 
of all ancestral cells limited to the 20 earliest branching events. The resulting 224 
distribution of mutational distances is shown in Figure 3a. We then use the same 225 
MCMC framework discussed above to jointly infer the mutation and cell survival 226 
rate. The MCMC algorithm rapidly converges to a fixed set of parameters ( 227 
Supplementary Figure 17). In Figure 3a and 3b we show the posterior parameter 228 
distributions after an initial burn in phase of 200 MCMC steps. In agreement with 229 
Lee-Six and colleagues, we find a mutation rate of ߤ = 1.14ି଴.ଶସା଴.ଵଶ mutations per 230 
genome per division (shown is the medium mutation rate per bp/cell-division 231 
and 95% credibility intervals inferred from the MCMC posterior parameter 232 
distribution), which corresponds to a mutation rate of ߤ = 3.9 × 10ିଵ଴ base 233 
pairs/division (assuming 3 × 10ଽbp in the human genome). Furthermore, we 234 
infer a per-cell survival rate of ߚ = 0.96ି଴.ଵ଴ଶା଴.଴ଷ଼, independently confirming the 235 
original assumption of almost perfect cell doubling during early development13.   236 
 237 
In vivo mutation and cell survival rate inference in single neurons 238 
during development 239 
In a recent publication, Bae and colleagues12 collected single neurons from 3 240 
fetuses 15 to 21 weeks post conception. Cells were expanded in culture and the 241 
whole genome was sequenced. Here we focus on the case where 14 whole 242 
genome sequenced single neurons were available (1 fetus 17w4d after 243 
conception). Again, we inferred all pairwise mutational differences, constructed 244 
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the corresponding distribution of mutational distances (Figure 4a) and used our 245 
MCMC framework for joint parameter estimates. The MCMC converges rapidly 246 
and we find sharply localised posterior distributions for the mutation and cell 247 
survival rate. We infer a median mutation rate of ߤ = 1.37ି଴.ଵା଴.ଵ mutations per 248 
genome per division (corresponding to a mutation rate of ߤ = 4.6 × 10ିଵ଴ base 249 
pair/division) and a per-cell survival rate of ߚ = 0.998ି଴.଴ଵା଴.଴଴ଶ. This inference 250 
agrees with Bae and colleagues original estimate of 1.3 mutations per genome 251 
per division based on a weighted average of all 3 fetuses, again assuming no cell 252 
death during early development. It also agrees with estimates of 1.2 mutations 253 
per division from de novo SNVs in familial trios26. The almost identical mutation 254 
rates in haematopoietic and brain tissue during early development may not be 255 
surprising. We would expect the DNA duplication and repair machinery to be 256 
stable across tissues during early development. It may even remain stable 257 
throughout live, as suggested by the linear rate of mutation accumulation with 258 
age across individuals27-29.  259 
 260 
In vivo mutation and cell survival rates in human tumours 261 
 262 
We then investigated the per-cell mutation and survival rates in individual 263 
tumours. We analysed whole genome or exome sequencing of 131 biopsies from  264 
16 tumours comprised of 1 colon adenoma, 7 colon carcinomas, 5 clear cell renal 265 
carcinomas and 2 lung squamous cell carcinomas (Table 1). When whole genome 266 
sequencing was available, the mutational load was sufficient to apply the 267 
inference framework to each chromosome separately (Figure 5 and 268 
Supplementary Figures 1-9). The analysis was restricted to regions of 269 
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chromosomes with same copy number profile in all samples of a tumour and 270 
inferences were normalised by copy-number and genome content. The 271 
resolution to infer the distribution of mutational distances from tumours was 272 
lower compared to healthy haematopoiesis or brain during development. 273 
Nevertheless, in most cases, the reconstructed distributions recover important 274 
features of the theoretical distribution (Supplementary  Figures 1-9 and 14). We 275 
found that mutation rates per cell division were 4 to 100 times higher in tumours 276 
compared to healthy tissue, ranging from 2.91 × 10ିଽ (bp/division) in the colon 277 
adenoma to 53 × 10ିଽ (bp/division) in one lung squamous cell carcinoma (Table 278 
1). Mutation rates differ significantly between patients but not across 279 
chromosomes of the same patient (Supplementary Figures 11 and 12). Overall 280 
this suggests important differences in mutation accumulation at the single cell 281 
level between tumours and is in agreement with recent experimental in vitro 282 
single cell mutation rate inferences29,30.  283 
 284 
To further unravel the underlying differences in mutation accumulation during 285 
tumour growth, we decomposed somatic mutations into the most prevalent 286 
trinucleotide mutational signatures31 for three whole-genome sequenced 287 
colorectal carcinomas and inferred per-cell mutation and per-cell survival rates 288 
per signature in each chromosome (Figure 5). Again, we find significant 289 
differences between patients (Supplementary Figure 13), further supporting 290 
inter-tumour differences of mutation accumulation at the single cell level.  291 
 292 
The inter-patient variation of the cell survival rate was evident. Whereas in 293 
healthy tissue almost all cells survive during development, in tumours cell 294 
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survival rates vary between 0.34 in one MSI+ colon carcinoma up to 0.86 in one 295 
renal cell carcinoma (Table 1). Again, per-cell survival rates were overall 296 
consistent if inferred from chromosomes of individuals, but varied significantly 297 
between patients (Figure 6 and Supplementary Figure 12). The underlying 298 
reasons for this inter-patient variation may be cell intrinsic and/or extrinsic, e.g. 299 
high cell death due to genomic instability, high mutational burden or immune 300 
surveillance. It will be of high interest to further unravel these differences on a 301 
patient specific basis in future studies. It should be noted that the inferred cell 302 
survival rates are high compared to previous estimates32,33. This is a direct 303 
consequence of the joint inference of mutation and cell survival rates that was 304 
not possible in earlier work. 305 
 306 
Discussion 307 
Here we presented a framework that allows disentangling the microscopic 308 
evolutionary forces of mutation and survival rates per cell division in humans 309 
from single time point measurements. Leveraging data on mutations in healthy 310 
haematopoiesis13 and brain tissue12, we found, in agreement with previous 311 
estimates, mutation rates of 1.14 and 1.37 mutations per whole genome per cell 312 
division. Mutation rates were 4 to 100 times higher in cancers and showed 313 
considerable inter-patient variation.  314 
 315 
The inference framework presented here relies on some assumptions. Mutation 316 
and cell survival rates are kept constant trough time and spatial location. We do 317 
not consider significant changes in cell fitness during growth and/or spatial 318 
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resource constraints. These limitations are more important for tumour specific 319 
inferences and less relevant for healthy tissue. The exact temporal and spatial 320 
change of the underlying microscopic evolutionary parameters over the lifetime 321 
of an individual tumour remains an open question. In some cases, there is 322 
evidence for singular catastrophic events34 and mutational signatures may 323 
change between resection and relapse35. However, it will also be important to 324 
disentangle mutation and cell population dynamic processes in these cases. A 325 
more fine-grained sampling over space and time is needed to better access if and 326 
how evolutionary parameters change within tumours. Given the technological 327 
advances in single cell genomics36,37, sequencing of potentially thousands of 328 
single cells would lead to significant information gain. This will allow probing 329 
potential changes of these evolutionary parameters over time.  330 
 331 
Furthermore, we expect the inter-patient variation of per-cell mutation and 332 
survival rates to directly influence clinically important variables, such as the 333 
likelihood of pre-existing treatment resistance38, tumour age and 334 
aggressiveness39. Measuring microscopic evolutionary forces in humans allows 335 
for a mechanistic foundation for precision medicine.  336 
 337 
 338 
 339 
 340 
 341 
 342 
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Methods 343 
 344 
Branching distribution in exponentially growing populations 345 
To calculate the expected distribution of branching events in an exponentially 346 
growing population, we can make use of coalescence theory20,21. Note that in 347 
coalescence theory one usually uses a backward time convention. If a population 348 
grows exponentially with ܰ(߬) = ݁ఉఛ, coalescence considers backward time 349 
ݐ = −߬ such that populations effectively shrink exponentially. The probability of 350 
coalescence ఍ܲ(ݐ) at time ݐ in an exponentially growing population is given by  351 
 352 
                              ఍ܲ(ݐ) = ଵே(௧) ∏ [1 −
ଵ
ே(௦)] ≈
௘ഁ೟
ேబ
௧ିଵ௦ୀ଴ exp ቀଵି௘
ഁ೟
ఉேబ ቁ,                                 (8) 353 
 354 
where ܰ(ݐ) is the size of the growing population at time ݐ. In our case, we are 355 
concerned with mutational distances and thus we ask for the distribution of 356 
times between coalescence events Δݐ rather than the distribution of coalescence 357 
times ݐ. However, we can directly infer this distribution from equation (8), by 358 
rewriting Δݐ = ݐ଴ − ݐ as the time of the initiating cell population at some point in 359 
the past. By substituting ݐ଴ = log( ଴ܰ) /(ߚ), we have Δݐ = ୪୭୥(ேబ)ఉ − ݐ and we find 360 
for the distribution of times between coalescence events 361 
 362 
                          ܲ(Δݐ) = ܲ ቀ୪୭୥(ேబ)ఉ − ݐቁ = ݁ିఉ୼௧ exp ቀ
ଵିேబ௘షഁ౴೟
ఉேబ ቁ.                              (9) 363 
 364 
This is for large ଴ܰ well approximated by  365 
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 366 
                                            ܲ(Δݐ) = ݁ିఉ୼௧ exp ቀ− ௘షഁ౴೟ఉ ቁ.                                                 (10) 367 
 368 
We show the validity of this approximation in Supplementary Figure 16. The 369 
normalized expression holds for all ଴ܰ ≥ 1. We can discretise this probability 370 
density function to derive at the probability for the number of branching 371 
divisions ݎ via 372 
 373 
ܲ(ݎ) = න ݀(Δݐ) ܲ(Δݐ) = න ݀(Δݐ) 
௥ାଵ
௥
௥ାଵ
௥
݁ିఉ୼௧ exp ቆ− ݁
ିఉ୼௧
ߚ ቇ 
                                            = exp ቀ− ௘షഁ(ೝశభ)ఉ ቁ − exp ቀ−
௘షഁೝ
ఉ ቁ.                                        (11) 374 
 375 
As we are interested in positive branch length only, we need to normalise the 376 
distribution for non-negative integers such that 1 = ଵ஼ ∑ ܲ(ݎ = ݅)ஶ௜ୀଵ . The 377 
normalising factor is ܥ = 1 − exp ቀ− ௘షഁఉ ቁ, and the distribution of branching 378 
divisions ݎ in an exponentially expanding cell population becomes  379 
 380 
                                           ܲ(ݎ) =
ୣ୶୮ቆି೐షഁ(ೝశభ)ഁ ቇିୣ୶୮ቆି
೐షഁೝ
ഁ ቇ
ଵିୣ୶୮൬ି೐షഁഁ ൰
.                                            (12) 381 
 382 
Equation (12) together with equation (6) in the main text allows a complete 383 
description of the expected distribution of mutational distances in exponentially 384 
growing populations. It has to be noted that the coalescence approximation used 385 
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here is based on a deterministic exponential growth function. It is known that 386 
such approaches do not always fully capture the full stochasticity especially at 387 
small population sizes and birth-death processes often perform better22. The 388 
individual based computer simulations used here are implementations of the 389 
Gillespie algorithm and are exact numerical representations of the underlying 390 
stochastic process. However, a further analysis on the stochasticity of the 391 
process for small population sizes is warranted.  392 
 393 
Interpretation of effective survival rate  394 
 395 
Throughout the manuscript we use the concept of the effective cell survival rate 396 
ߚ. One can also formulate cell death with a microscopic perspective given a 397 
probability ߙ for a daughter cell to die (or differentiate) after division. Such a 398 
probability allows for three outcomes after a cell division: with probability 399 
(1 − ߙ)ଶ both daughter cells survive, with probability 2ߙ(1 − ߙ) one daughter 400 
cell survives and with probability ߙଶ both daughter cells die. However, as we are 401 
bound to find surviving cell lineages in every possible measure of tumours, none 402 
of the observed cell lineages can have gone extinct. Mathematically, this implies 403 
that measurement conditions cell division on non-extinction of both daughter 404 
cells and we can write 405 
 406 
ߚ ≡ ܲ(ݏݑܿܿ݁ݏݏ݂ݑ݈ ݀݅ݒ݅ݏ݅݋݊| ݊݋݊ ݁ݔݐ݅݊ܿݐ݅݋݊) = ௉(௦௨௖௖௘௦௦௙௨௟ ௗ௜௩௜௦௜௢௡ & ௡௢௡ ௘௫௧௜௡௖௧௜௢௡)௉(௡௢௡ ௘௫௧௜௡௖௧௜௢௡) . 407 
 408 
With the corresponding probabilities ߙ we get  409 
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 410 
                                                         ߚ = (ଵିఈ)మଵିఈమ =
ଵିఈ
ଵାఈ.                                                          (13) 411 
 412 
We also can rearrange equation (13) to solve for ߙ,  413 
 414 
                                                                  ߙ = ଵିఉଵାఉ.                                                                  (14) 415 
 416 
If we interpret ߙ as the probability of random cell death after a division, ߙ must 417 
be smaller than 1/2. If ߙ were larger than 1/2, tumour populations extinct 418 
almost surely after sufficiently many cell divisions. This implies ߚ > 1/3 for 419 
growing populations.  420 
 421 
Simulations of mutation accumulation in growing tissues 422 
We simulated cell populations of ~1 million cells on a grid with varying birth 423 
death and mutation rates using an implementation of the Gillespie algorithm 424 
based on code published in23. The code is available at 425 
https://github.com/sottorivalab/CHESS.cpp. A cell division produces two 426 
surviving cells with probability ߚ or one surviving cell with probability 1 − ߚ. 427 
During each division, each daughter cell inherits the mutations of its parent and 428 
in addition accumulates novel mutations. The number of novel mutations is 429 
drawn from a Poisson distribution with mean ߤ. During simulations, the 430 
mutations for each cell as well as the division history of each cell are recorded.  431 
 432 
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We took samples (between 1 and 10k cells per sample) from each simulated 433 
tumour. For most inferences, we used maximal distance sampling. Sequencing 434 
errors were simulated for each bulk by binomial sampling assuming sequencing 435 
depths of 100x, by generating dispersed coverage values for input mutations. We 436 
do that by sampling a coverage from a Poisson distribution: Poisson(λ = Z) with 437 
mean ߣ equal to a desired sequencing depth ܼ. Once we have sampled a depth 438 
value k for a mutation, we sample its frequency (number of reads with the 439 
variant allele frequency) with a Binomial trail. We use ݂ ∼ Binomial(݊, ݇), where 440 
݊ is the proportion of cells carrying this mutation given all cells sampled in the 441 
simulated biopsy. This generates realistic mutation distributions comparable to 442 
available genomic sequencing data.  443 
 444 
Bayesian parameter inference 445 
We use a Markov chain Monte Carlo method (MCMC) to recover the mutational 446 
distance ߤܮ and the cell survival rate ߚ  given a measured distribution of 447 
mutational distances. More precisely we implemented a standard Metropolis-448 
Hastings-algorithm following below steps: 449 
(i) Create a new random set of model parameters ࢝ given the current set 450 
of parameters ࢜ from a defined probability density ܳ, such that 451 
ܳ(ݔ|ݕ) = ܳ(ݕ|ݔ).  452 
(ii) Calculate the likelihood ܮ(ܲ(࢝)) of the model distribution ܲ(࢝) given 453 
the data. 454 
(iii) Calculate the ratio of the new and old likelihood ߩ = ܮ(ܲ(࢝))/455 
ܮ(ܲ(࢜)). Accept the new parameter set with probability ߩ otherwise 456 
reject.  457 
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(iv) Repeat 458 
In our case the model distribution is given by equation (7) in the main text. To 459 
calculate the likelihood of equation (7) given the data, we have to choose a cut off 460 
for the infinite sums. However, real data always has a maximum mutational 461 
distance. Higher terms of the infinite sums contribute to higher mutational 462 
distances. The distribution of interest does not change for a sufficiently high cut 463 
off and each observed data set only requires finite many terms. Here we used 464 
ݎ = ݅ = 30 as upper cut-off, which is a conservative choice. We used uninformed 465 
uniform prior distributions for mutational distance ߤܮ and the per-cell survival 466 
rate ߚ in all cases. Point estimates were extracted as sample medians from the 467 
MCMC inferences. The ranges of the uniform priors were adjusted to optimise 468 
acceptance rates and computational time. In our implementation, a new set of 469 
parameters is relative to the previously accepted parameter set ࢝୒ୣ୵ = ࢝ை௟ௗ +470 
Φ(࢝), where Φ is the prior parameter distribution. A typical range used in our 471 
inference scheme is Φ୳୬୧୤୭୰୫(ߚ) = [−0.06, +0.06]  and Φ୳୬୧୤୭୰୫(ߤ) =472 
[−0.15, +0.15]. We also tested Gamma prior distributions and did not see 473 
differences in convergence. One numerical realisation of the Log-Likelihood 474 
function is shown in Supplementary Figure 18 and example traces of the MCMC 475 
algorithm are shown in Supplementary Figure 17. We also tested the influence of 476 
sequencing depth and spatial sampling strategies on the performance of the 477 
MCMC inference framework (Supplementary  Figures 19 & 20). The code for the 478 
MCMC inference is available at https://github.com/sottorivalab/MCMC-479 
MutationalDistances-. 480 
 481 
Mutational signature analysis 482 
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For each sample we found the set of signatures (among those signatures 483 
reported in CRC) that best explained the totality of mutations in the sample. We 484 
did a non-negative regression of the sample’s mutations against all the CRC 485 
signatures44 and found those signatures with non-zero coefficients. We took 486 
these as the candidate signatures for each sample.  487 
 488 
For each mutation in each sample, we determined the likelihood of the mutation 489 
under each of the candidate signatures. We assigned a mutation to a candidate 490 
signature where the likelihood under that signature was at least twice that under 491 
any other. If there was no such signature, we assigned the mutation to “Other”. 492 
The method was originally developed in44 and is based on the R-package 493 
“SomaticSignatures”45. We did not adjust for differences in nucleotide 494 
composition when calculating differences between coding and non-coding 495 
regions as we wanted to infer the overall point mutation rate in these regions. 496 
Nucleotide dependent mutation rate estimates are shown in Supplementary 497 
Figures  10 and 15. Nucleotide composition was adjusted for to calculate the 498 
mutation rates of mutational signatures using standard tools45. 499 
 500 
Data availability  501 
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 506 
 22
Acknowledgments 507 
A.S. is supported by the Wellcome Trust (202778/B/16/Z) and Cancer Research 508 
UK (A22909). T.G. is supported by the Wellcome Trust (202778/Z/16/Z) and 509 
Cancer Research UK (A19771). We acknowledge funding from the National 510 
Institute of Health (NCI U54 CA217376) to A.S and T.A.G. This work was also 511 
supported a Wellcome Trust award to the Centre for Evolution and Cancer 512 
(105104/Z/14/Z). C.P.B. acknowledges funding from the Wellcome Trust 513 
(209409/Z/17/Z). 514 
 515 
Author Contributions 516 
B.W. and A.S. conceived the study. B.W. and J.C. performed mathematical 517 
analysis. B.W., M.J.W., K.C., D.T., J.F.M., G.D.C., D.N. W.C., I. S., W.H. & I.T. 518 
contributed to data analysis and simulations. A.S. and T.A.G. supervised the 519 
study. B.W., C.P.B., T.A.G. & A.S. wrote the manuscript. All authors read and 520 
approved the manuscript.  521 
 522 
Competing Interests  523 
The authors declare no competing interests.  524 
 525 
Code availability  526 
The code for stochastic simulations of tumour growth is available at 527 
https://github.com/sottorivalab/CHESS.cpp. The code for the MCMC inference is 528 
available at https://github.com/sottorivalab/MCMC-MutationalDistances-. 529 
 530 
 23
 531 
Figure Legends 532 
 533 
Figure 1: Multi-region bulk sequencing encodes information on single cell lineages and 534 
single cell divisions. a) Each of the seven spatially separated tissue samples (in grey) consists of 535 
thousands to millions of cells that descended from a single most recent common ancestor 536 
(MRCA) cell. The genomic make-up of the single ancestral cell is described by the mutations 537 
clonal to the bulk sample. Those appear at high variant allele frequency in the sample (bottom-538 
left panel, in purple). The intersection of mutations in any two bulk MRCA cells corresponds to 539 
the genomic profile of another more ancestral cell. This process continues back in time until the 540 
MRCA cell of all the sampled cells is reached. b) The level of genomic variation within a growing 541 
tissue (e.g. development or cancer) is the direct consequence of mutation accumulation during 542 
cell divisions, leading to a branching structure. Importantly, the most fundamental parameters, 543 
the mutation rate ߤ and survival rate ߚ of cells per division that drive this process are not directly 544 
observable. c) Mutation rate per division ߤ and cell survival rate ߚ leave identifiable fingerprints 545 
in the observable patterns of genetic heterogeneity within a tissue. Cell divisions occur in 546 
increments of natural numbers and thus the mutational distance between any two ancestral cells 547 
is a multiple of the mutation rate ߤ. 548 
 549 
Figure 2: Distribution of mutational distances and computational validation. a) The 550 
quantized nature of cell divisions leads to a characteristic predicted distribution of mutational 551 
distances across cell lineages. The shape of the distribution depends on the exact values of ߤ and 552 
ߚ. Roughly four different scenarios of combinations of small and large ߤ and ߚ are possible. They 553 
influence the shape of the distribution differently and thus constructing the distribution of 554 
mutational distances allows disentangling the mutation rate ߤ and cell survival rate ߚ. b) Spatial 555 
stochastic simulations confirm the ability of mutational distance distributions to disentangle 556 
mutation and lineage expansion rates (red area shows the spatial spread of a subclonal 557 
mutation). Dots show mutational distances inferred from 200 samples of a single stochastic 558 
computer simulation (ߤ = 20, ߚ = 0.95), the dashed line is the predicted distribution based on 559 
our equation 7. c) A Monte Carlo Markov Chain inference framework based on mutational 560 
distance distributions reliably identifies mutation and lineage expansion rates in simulations of 561 
spatial and stochastically growing tissues (2 dimensional spatial stochastic simulations, ߤ: 562 
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Spearman Rho = 0.98, ݌ = 4 × 10ିଶଷ ; ߚ: Spearman Rho = 0.93, ݌ = 8 × 10ିଵ଺ , Relative error: 563 
ߟఓ = 0.056, ߟఉ = 0.045). 564 
 565 
Figure 3: Per-cell mutation and per-cell survival rate inferences in healthy haematopoiesis 566 
during development. a) Mutational distance distribution inferred from 89 whole genome 567 
sequenced healthy haematopoietic stem cells from ref13 (black dots), and best theoretical fit 568 
(grey line). Posterior parameter distribution of the MCMC inference for b) the mutation rate per 569 
cell division (ߤܮ = 1.14ି଴.ଶସା଴.ଵଶ mutations per genome per cell division) and c) the cell survival rate 570 
(ߚ = 0.96ି଴.ଵ଴ଶା଴.଴ଷ଼). Median point estimates and 95% credibility intervals were taken from the 571 
posterior parameter distributions. The inferred mutation rate per cell division agrees with the 572 
original estimation of 1.2 mutations per cell division. Furthermore, our joined inference of 573 
mutation and cell survival rate confirms the original assumption of no cell death during early 574 
development of haematopoiesis.  575 
 576 
Figure 4: Per-cell mutation and per-cell survival rate inferences in single neurons during 577 
development a) Mutational distance distribution inferred from 14 whole genome sequenced 578 
single neurons from ref12 derived from one fetus (17w4d past conception) (black dots), and best 579 
theoretical fit (grey line). MCMC inference for b) the mutation rate per cell division (ߤܮ =580 
1.37ି଴.ଵା଴.ଵ mutations per genome per cell division) and c) the per-cell survival rate (ߚ =581 
0.998ି଴.଴ଵା଴.଴଴ଶ). Median point estimates and 95% credibility intervals were taken from the posterior 582 
parameter distributions. The inferred mutation rate per cell division agrees with the original 583 
estimation of 1.3 mutations per cell division. Furthermore, our joined inference of mutation and 584 
cell survival rate confirms the original assumption of no cell death during early brain 585 
development.  586 
 587 
Figure 5: Mutational distance for three colorectal tumours. a-c) Examples of the mutational 588 
distance distribution on single chromosomes for three different colorectal carcinomas for which 589 
6, 7 and 9 multi-region bulk samples were sequenced at whole-genome resolution (dots=data, 590 
dashed line=theoretical prediction based on MCMC parameter estimates – see insets). The 591 
distribution of mutational distances differs between patients, with Patient 04 (MSI – 592 
Microsatellite Instability) showing one order of magnitude larger mutational distances. d-f) Per-593 
cell mutation rate per chromosome separated by trinucleotide mutational signature. Results are 594 
consistent across chromosomes, as expected (Methods). g-i) The mean overall mutation rates are 595 
(ߤ଴ଶ = (1.0ି଴.଴଻ା଴.ସ଺)  × 10ି଼, ߤ଴ଷ = (2.4ି଴.ଵଽା଴.ସଵ)  × 10ି଼ and ߤ଴ସ = (3.1ି଴.ଵଶା଴.ଷହ) × 10ି଼ bp/division , 596 
dashed lines), 20 to 60 times higher compared to healthy somatic cells. Patient 04 is MSI+ 597 
highlighted by signature 6. j-l) Estimates of per-cell survival rates per chromosome are 598 
consistent across chromosomes of the same patient (Median: 599 
ߚ଴ଶ = 0.51ି଴.଴ହା଴.଴ହ, ߚ଴ଷ = 0.65ି଴.଴ଶା଴.଴ଶ, ߚ଴ସ = 0.34ି଴.଴ଵା଴.଴ଵ ), but vary considerably between patients 600 
(Supplementary Figure 12).  601 
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 602 
Figure 6: Map of per-cell mutation and per-cell survival rates across cancer types. For each 603 
of the 16 tumours analysed we plot the per-cell mutation rate versus the per-cell survival rate. 604 
Median estimates and 95% credibility intervals for the mutation and cell survival rate are 605 
derived from the MCMC inferences as described in the main text. Dashed lines correspond to 606 
values of healthy tissue (ߤ௛ = 1 × 10ିଽ, ߚ௛ = 1/3). White background corresponds to ߚ values 607 
that allow for growing cell populations as ߚ = 1/3 corresponds to stable (homeostatic) 608 
populations. Shaded area describes values of ߚ that would lead to population extinction. Most 609 
cancers scatter across the map, indicating extensive inter-patient heterogeneity.  610 
 611 
 612 
 613 
 614 
 615 
Tissue type Sequencing # Samples ࣆ
× ૚૙ିૢ 
ࢼ Source 
HSC (development) Whole Genome 89 0.39 0.96 Lee-Six 
Neuron (development) Whole Genome 14 0.46 0.99 Bae
CRA Exome 6 2.91 0.46 Cross 
CRC (MSS) Exome 13 30.1 0.84 Cross 
CRC (MSS) Exome 8 12.5 0.43 Cross 
CRC (MSS) Whole Genome 6 24.0 0.65 Cross 
CRC (MSS) Whole Genome 7 10 0.51 Cross 
CRC (MSS) Whole Genome 9 8.9 0.45 Roerink 
CRC (MSS) Whole Genome 9 9.9 0.50 Roerink 
CRC (MSI) Whole Genome 9 30.9 0.34 Cross 
CRC (MSI) Whole Genome 7 17.9 0.47 Roerink 
CCRCC Exome 8 21.7 0.66 Gerlinger 
CCRCC Exome 11 31.2 0.86 Gerlinger 
CCRCC Exome 8 15.8 0.47 Gerlinger 
CCRCC Exome 8 2.3 0.80 Gerlinger 
CCRCC Exome 8 2.1 0.72 Gerlinger 
NSCLC Exome 7 53 0.36 Jamal-Hanjani 
NACLC Exome 7 14 0.59 Jamal-Hanjani 
 616 
Table 1: Data summary and evolutionary parameter inferences. The data of healthy tissue 617 
during development was taken from Lee-Six et al13 and Bae et al12. Data on colorectal cancers is 618 
from Cross et al40 and Roerink et al41, data on renal cell carcinoma from Gerlinger et al42 and data 619 
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on lung carcinomas from Jamal-Hanjani et al43. Estimates for mutation and cell survival rates are 620 
from best MCMC fits based on the distribution of mutational distances.  621 
 622 
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